Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03065699
Other study ID # YAQ-002
Secondary ID CIV-16-08-016644
Status Completed
Phase N/A
First received
Last updated
Start date July 9, 2017
Est. completion date January 15, 2020

Study information

Verified date May 2021
Source Yaqrit Ltd
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The First-In-Man study is a multi-centre, randomised, controlled, study to generate data for the evaluation of safety and performance of DIALIVE Liver Dialysis Device in 24 evaluable patients with Acute on Chronic Liver Failure (ACLF) versus standard of care (SOC).


Description:

The First-In-Man study will evaluate the safety and performance of DIALIVE Liver Dialysis Device in Acute on Chronic Liver Failure (ACLF) patients and will compare the outcome with patients treated under standard of care (SOC). The hypothesis is that DIALIVE will significantly improve the prognosis of ACLF patients by modulating systemic inflammation. The target patient population are men and women ≥18 years, ≤81yr. Patients with ACLF grade 1 and ACLF grade 2 on the background of alcoholic cirrhosis. During the study, inclusion criteria were expanded to include also AKI-1 and ACLF 3a patients. Treatment will be undertaken in an intensive care (ICU) or renal dialysis unit setting if the patients are randomised to the DIALIVE treatment arm. For patients randomised to the 'Standard of care' arm, the location of treatment (ICU or general ward) will be determined by their clinical need and will be decided by the site Principal Investigator. This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 733057.


Recruitment information / eligibility

Status Completed
Enrollment 30
Est. completion date January 15, 2020
Est. primary completion date December 31, 2019
Accepts healthy volunteers No
Gender All
Age group 18 Years to 81 Years
Eligibility Inclusion Criteria: - Male or female subjects aged =18 years =81yr who have given informed consent to participate in the study and are able to understand and comply with the requirements of the study (otherwise written informed consent must be obtained on behalf of the subject in accordance with local ethical and legal requirements). - History indicative of alcohol-related cirrhosis based on clinical, radiological and/or histological evidence. - History of an acute decompensating event (including but not limited to ascites, gastrointestinal bleeding, hepatic encephalopathy and/or acute bacterial infections), occurring within =6 weeks of screening. - • Subject with : - ACLF Grade 1, 2 or 3a defined per the CLIF-C OF scoring system OR - single hepatic organ failure for serum bilirubin > 20 mg/dL (342 µmol/L) at screening and randomization, OR - AKI-stage 1b (sCr > 1.5 mg/dL or 134 µmol/L). - Where a subject has received corticosteroids for alcohol-induced ACLF, is unresponsive to at least 7 days of treatment (where lack of response defined as Lille score > 0.45 or steroids stopped before 7 days due to any complication such as infection). This refers to the first course of corticosteroid therapy only. Exclusion Criteria: - Co-infection with HIV and AIDS defining illness. - Subjects with acute or sub-acute liver failure without underlying cirrhosis. - Subjects with severe thrombocytopaenia, defined by the platelet count of < 40,000 / mm3 or rapid reduction in platelet count (> 50% reduction) 24 hrs prior to inclusion. - Subjects with International Normalised Ratio (INR) > 3 - ACLF 3b patients, i.e. ACLF with more than 3 organ failures. - Subjects with cirrhosis who develop decompensation at any time in the post-operative period following partial partial liver resection or major non-liver surgery. - Subjects with uncontrolled infection. Patients may be entered into the study provided antimicrobials have been administered for at least 48 hours with an appropriate response observed prior to randomization. - Subjects with respiratory organ failure (as per CLIF-C OF scoring: PaO2/FiO2< 200 mmHg or 27 kPa or SaO2/FiO2 < 214). - Subjects with haemodynamic instability: i) persistent hypotension (mean arterial pressure < 65 mmHg) with evidence of tissue hypoperfusion, not responsive to volume resuscitation and/or low dose vasopressor support; ii) a norepinephrine dose of > 0.2 µg/kg/min, or a second pressor (terlipressin for variceal haemorrhage and/or hepato-renal syndrome does not count as pressor, unless it is specifically used to treat systemic hypotension) at screening or randomization. Patients can be reconsidered for study inclusion after at least a 24 hour period of norepinephrine requirement < 0.2 µg/kg/min. - Subjects not considered appropriate for full active treatment including organ support or those with a Do Not Attempt Cardio-Pulmonary Resuscitation order (DNACPR). - Subjects with active, or with a history of non hepatic malignancy unless adequately treated or in complete remission for five or more years. - Patients with HCC outside Milan criteria. - Significant systemic or major illness other than liver disease, including coronary artery disease, cerebrovascular disease, pulmonary disease, renal failure, serious psychiatric disease, that, in the opinion of the Investigator would preclude the subject from participating in and completing the study. - Subject who has received any investigational drug or device within 30 days of dosing or who is scheduled to receive another investigational drug or device in the course of the study; concomitant observational studies are allowed. - Evidence of uncontrolled seizures. - Subjects diagnosed with Creutzfeldt-Jakob disease. - In females: known pregnancy or lactating. - Subjects weighing less than 30 kg (as per contra-indications of oXiris and septeX) - Where subjectspresent with a known allergy to heparine of have type II thrombocytopaenia caused by heparin (HIT syndrome type II) - In the opinion of the investigator, it is unsafe for the patient to be considered for the study.

Study Design


Intervention

Device:
DIALIVE Liver Dialysis Device
ACLF patients will receive dialysis treatment for 8-12 hrs/day and on three to five consecutive days over a 10-day time period. Dialysis treatment is performed by using the DIALIVE device provided by YAQRIT Ltd.

Locations

Country Name City State
Austria university Hospital Graz Graz
Belgium University Hospital Erasmus Brussels
Denmark University Hospital Aarhus
France Hôpital Beaujon Clichy
France Paul Brousse Hospital Villejuif
Germany University Hospital of Rostock Rostock
Romania Fundeni Clinical Institute Bucharest
Spain Hospital Clinic Barcelona Barcelona
Spain University Hospital Gregorio Maragnon Madrid
United Kingdom university hospital BASILDON Basildon
United Kingdom Royal Free Hospital London NHS London Hampstead
United Kingdom Queens Medical Centre Nottingham

Sponsors (4)

Lead Sponsor Collaborator
Yaqrit Ltd European Foundation for Chronic Liver Failure, Fakkel bvba, University College, London

Countries where clinical trial is conducted

Austria,  Belgium,  Denmark,  France,  Germany,  Romania,  Spain,  United Kingdom, 

References & Publications (1)

Lee KC, Baker LA, Stanzani G, Alibhai H, Chang YM, Jimenez Palacios C, Leckie PJ, Giordano P, Priestnall SL, Antoine DJ, Jenkins RE, Goldring CE, Park BK, Andreola F, Agarwal B, Mookerjee RP, Davies NA, Jalan R. Extracorporeal liver assist device to exchange albumin and remove endotoxin in acute liver failure: Results of a pivotal pre-clinical study. J Hepatol. 2015 Sep;63(3):634-42. doi: 10.1016/j.jhep.2015.04.020. Epub 2015 May 1. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Other Efficacy of the DIALIVE for liver function: changes in MELD score Outcome measure as compared between SoC and DIALIVE arm is:
Liver: Changes in MELD score, plasma/serum cCK18/M30 and flCK18/M65 (markers of liver cell death).
Liver: serum bilirubine Model for End-Stage Liver Disease (MELD) Scoring Systems.
Treatment period is from 1 to 10 days post-randomization
Other Efficacy of the DIALIVE for kidney function: changes in creatine and NGAL Outcome measure as compared between SoC and DIALIVE arm is:
- Kidney: Changes in serum creatinine and urinary NGAL (Neutrophil gelatinase-associated lipocalin - marker of kidney injury).
Treatment period is from 1 to 10 days post-randomization
Other Efficacy of the DIALIVE for brain function: changes in West Haven Criteria Outcome measure as compared between SoC and DIALIVE arm is:
- Brain: West Haven Criteria to assess changes in severity of hepatic encephalopathy.
Treatment period is from 1 to 10 days post-randomization
Other Efficacy of the DIALIVE for immune function. Outcome measure as compared between SoC and DIALIVE arm is:
- Immune function: Incidence of Infection. Changes in white cell count and plasma-induced neutrophil function (Phagoburst and Phagotest), serum CRP and cytokines (TNF-a, IL-6, IL-8, IL-10, IL1RA).
Treatment period is from 1 to 10 days post-randomization
Other Assessment of coagulation and haemostasis. Outcome measure as compared between SoC and DIALIVE arm is:
- Coagulation: Changes in INR and platelet levels.
Treatment period is from 1 to 10 days post-randomization
Other Efficacy of the DIALIVE for pulmonary function. Outcome measure as compared between SoC and DIALIVE arm is:
- Lung: P/F or S/F ratio.
Treatment period is from 1 to 10 days post-randomization
Other Efficacy of the DIALIVE for the cardiovascular function. Outcome measure as compared between SoC and DIALIVE arm is:
- Cardiovascular system: measurement off the Mean Arterial Pressure.
Treatment period is from 1 to 10 days post-randomization
Primary Safety of DIALIVE in terms of percentage of ACLF patients experiencing serious adverse events during DIALIVE treatment period. To evaluate the safety of the DIALIVE device in patients with Acute on Chronic Liver Failure Grades 1 and 2 (ACLF). Outcome measure is: The percentage of subjects who experience at least one (1) serious adverse event (SAE) between Day 1 and Day 10.(DIALIVE arm only).
Outcome is measured on day 10 and compared between treatment arms.
Treatment period is from 1 to 10 days post-randomization.
Primary Safety of DIALIVE in terms of percentage of ACLF patients who discontinued treatment due to severe adverse event. The outcome measure is the percentage of subjects who discontinued DIALIVE treatment due to a serious adverse device event (SADE) between Day 1 (first day of treatment) and Day 10.(DIALIVE arm only) Treatment period is from 1 to 10 days post-randomization.
Secondary Performance of DIALIVE by assessing removal of endotoxins. To evaluate the performance of the DIALIVE device in patients with ACLF (DIALIVE arm only). Outcome measure is :
- Change in Plasma endotoxin concentrations between end of treatment with DIALIVE and the beginning of treatment with DIALIVE (Day 1).
TV: 40% reduction; AV: 20% reduction
End of DIALIVE treatment (max 10 days after randomization)
Secondary Performance of DIALIVE by assessing removal of albumin. To evaluate the performance of the DIALIVE device in patients with ACLF (DIALIVE arm only). Outcome measure is :
- Change in Albumin function (Human non-mercapt albumin -2 (HNA-2) / Human mercapt albumin (HMA ratio) between end of treatment with DIALIVE and the beginning of treatment with DIALIVE (Day 1)
End of DIALIVE treatment (max 10 days after randomization)
Secondary Change in Clinical Parameters by DIALIVE treatment (ACLF grade and score) between treatment arms. Evaluate the improvement in clinical parameters between Acute on Chronic Liver Failure (ACLF) patients receiving DIALIVE treatment vs Standard of Care. Outcome measure is:
- Change in CLIF-C score (Chronic LIver Failure Consortium)
Treatment period is from 1 to 10 days post-randomization
Secondary Change in Clinical Parameters by DIALIVE treatment (ACLF grade) between treatment arms. Evaluate the improvement in clinical parameters between Acute on Chronic Liver Failure (ACLF) patients receiving DIALIVE treatment vs Standard of Care. Outcome measure is:
- Change in ACLF Grade
Treatment period is from 1 to 10 days post-randomization
Secondary Change in mortality between treatment arms. The outcome measure is the difference in mortality between the DIALIVE treatment arm and the Standard of Care arm at day 28 post-randomization.
During the study, the follow up period was prolonged to 90 days (3 months).
At day 28 post-randomization (for all patients). At day 90 for those patients enrolled under protocol version 6.0.
Secondary Change in Clinical Parameters by DIALIVE treatment (CLIF-C score) between treatment arms. Evaluate the improvement in clinical parameters between Acute on Chronic Liver Failure (ACLF) patients receiving DIALIVE treatment vs Standard of Care. Outcome measure is:
- Change in CLIF-C score (Chronic LIver Failure Consortium)
Treatment period is from 1 to 10 days post-randomization
Secondary Status of ICU and hospital discharge. Location of patient at day 28 and 90 post randomization, and timing of discharge from hospital. Treatment period is from 1 to 90 days post-randomization.
Secondary Length of stay in ICU and in hospital Evaluation of length of stay of patient in the hospital and on the ICU. Assessment is done on day 28 and day 90.
Secondary ICU and hospital re-adminssions with another episode of ACLF Assessment of re-admissions of patients for another episode of ACLF after hospital discharge post-randomization. Assessment is done on day 28 and day 90.
See also
  Status Clinical Trial Phase
Not yet recruiting NCT06069284 - Prognostic Significance of Acute Change in Liver and Splenic Stiffness in Patients of Acute on Chronic Liver Failure
Recruiting NCT03754400 - Efficacy of Albumin Therapy With Standard Medical Treatment (SMT) as Compared to Standard Medical Treatment (SMT) in Improving Patient Survival and Immune Modulation in Patients With Acute on Chronic Liver Failure (ASIA Trial). N/A
Not yet recruiting NCT06066814 - To Study the Role of Plasma Von Willebrand Factor Antigen (vWF) to A Disintegrin-like and Metalloproteinase With Thrombospondin Type-1 Motifs 13 (ADAMTS-13) Activity Ratio as a Predictor of Development of Extrahepatic Organ Failure in Acute on Chronic Liver Failure (ACLF) Patients.
Completed NCT02573727 - To Compare the Response Rate of Noradrenaline vs. Terlipressin in Hepatorenal Syndrome in Patients With Acute on Chronic Liver Failure N/A
Completed NCT02583698 - Efficacy of Nonselective Beta Blocker vs Placebo in Patients With Acute-on-chronic Liver Failure With Small/ no Esophageal Varices N/A
Not yet recruiting NCT06116305 - Lactate Kinetics as a Predictor of Survival in ACLF With Septic Shock
Completed NCT01074645 - Randomized Controlled Trial of Tenofovir in Patients of Reactivation of Hepatitis B Presenting as Acute on Chronic Liver Failure Phase 4
Recruiting NCT05124041 - Goal-Directed Hemostatic Resuscitation Trial in ACLF Induced Coagulopathy N/A
Not yet recruiting NCT06340269 - Feasibility Pilot Study to Evaluate the Safety and Performance of the MEX-CD1 Medical Device in ACLF N/A
Recruiting NCT01866072 - Evaluation of Role of Transient Elastography (Fibroscan) in Differentiating Patients of Acute Severe Viral Hepatitis and Acute on Chronic Liver Failure N/A
Terminated NCT02788240 - To Study the Influence of GCSF on Natural History of Acute On Chronic Liver Failure After the Acute Phase N/A
Not yet recruiting NCT05772585 - Characterization of Metabolomic Fingerprints in Patients With Acute Liver Failure and Acute-on-chronic Liver Failure With Hepatic Encephalopathy
Withdrawn NCT05131230 - CytoSorb® in Patients With Acute on Chronic Liver Failure
Completed NCT02467348 - Incidence And Outcome Of Paracentesis Induced Circulatory Dysfunction In Acute-On-Chronic Liver Failure. N/A
Not yet recruiting NCT06276907 - An Open-label Randomized Controlled Trial Comparing the Role of Therapeutic Plasma-exchange in Ameliorating Secondary Organ Dysfunctions in Patients With ACLF and Develop Biomarkers of Treatment Response N/A
Recruiting NCT05146336 - CytOSorb TreatMent Of Critically Ill PatientS Registry
Completed NCT02307409 - Assessment of Coagulation Profile and Haematopoietic Responses in Patients With Acute-on-chronic Liver Failure During Systemic Inflammatory Response (SIRS) and Sepsis N/A
Recruiting NCT02757170 - Assessment of Coagulation Abnormalities in Acute on Chronic Liver Failure Patients Using Thromboelastography Phase 4
Recruiting NCT04054037 - A Study of AARC Standards on Diagnosis and Treatment of Patients With HBV-ACLF in China (AARC China Study)
Recruiting NCT05180292 - Acute Hemodynamic Response to Carvedilol in Predicting Survival in Acute on Chronic Liver Failure Patients - A Pilot Study. N/A